Key Points
Monocytes from CFTRΔF508 mice have a defect in β2 integrin–dependent adhesion.
Transferring WT bone marrow rescues CF disease.
Monocyte-specific CFTR knockout retards weight gains and exacerbates DSS-induced colitis.
Abstract
Cystic fibrosis (CF) is an inherited life-threatening disease accompanied by repeated lung infections and multiorgan inflammation that affects tens of thousands of people worldwide. The causative gene, cystic fibrosis transmembrane conductance regulator (CFTR), is mutated in CF patients. CFTR functions in epithelial cells have traditionally been thought to cause the disease symptoms. Recent work has shown an additional defect: monocytes from CF patients show a deficiency in integrin activation and adhesion. Because monocytes play critical roles in controlling infections, defective monocyte function may contribute to CF progression. In this study, we demonstrate that monocytes from CFTRΔF508 mice (CF mice) show defective adhesion under flow. Transplanting CF mice with wild-type (WT) bone marrow after sublethal irradiation replaced most (60–80%) CF monocytes with WT monocytes, significantly improved survival, and reduced inflammation. WT/CF mixed bone marrow chimeras directly demonstrated defective CF monocyte recruitment to the bronchoalveolar lavage and the intestinal lamina propria in vivo. WT mice reconstituted with CF bone marrow also show lethality, suggesting that the CF defect in monocytes is not only necessary but also sufficient to cause disease. We also show that monocyte-specific knockout of CFTR retards weight gains and exacerbates dextran sulfate sodium–induced colitis. Our findings show that providing WT monocytes by bone marrow transfer rescues mortality in CF mice, suggesting that similar approaches may mitigate disease in CF patients.
Footnotes
This work was supported by funding from the National Institutes of Health (HL078784 and R01HL145454), a pilot and feasibility award from the Cystic Fibrosis Foundation (00841I221), a WSA postdoctoral fellowship and career development award from the American Heart Association (16POST31160014 and 18CDA34110426), and a startup fund from UConn Health.
Experiments were designed by Z.F. and K.L. Most experiments were performed by Z.F., E.P., L.W., J.M., E.E., R.H., W.L., J.C., A.M., M.O., P.K., and Z.M. Data analysis was performed by Z.F., E.P., L.W., Y.P.Z., and P.M.M. A critical mouse strain was provided by C.A.H. The manuscript was written by K.L., Z.F., and D.C. The project was supervised by K.L., Z.F., V.A.R., K.W., and C.C.H. All authors discussed the results and commented on the manuscript.
The online version of this article contains supplemental material.
Abbreviations used in this article
- AF
- Alexa Fluor
- BALF
- bronchoalveolar lavage fluid
- BM
- bone marrow
- BMT
- bone marrow transplantation
- BV
- Brilliant Violet
- CF
- cystic fibrosis
- CFTR
- cystic fibrosis transmembrane conductance regulator
- DSS
- dextran sulfate sodium
- HSC
- hematopoietic stem cell
- LAD
- leukocyte adhesion deficiency
- LP
- lamina propria
- MFI
- mean fluorescence intensity
- RT
- room temperature
- WT
- wild-type
- Received September 25, 2021.
- Accepted November 19, 2021.
- Copyright © 2022 by The American Association of Immunologists, Inc.
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$37.50
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.